Research programme: ion channel modulators - Merck & Co
Alternative Names: Ion channel modulators research programme - ArQuleLatest Information Update: 20 Jan 2020
At a glance
- Originator ArQule
- Class
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 12 Feb 2004 Ion channel modulator is available for licensing (http://www.arqule.com)
- 13 Aug 2003 Preclinical trials in Neuropathic pain in USA (unspecified route)